Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms

Schizophrenia Bulletin(2025)10.1093/schbul/sbaf034Source: DataRank Database

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms is a research paper published in Schizophrenia Bulletin (2025). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.47)OA: hybridTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

I-Yuan Liu,Celso Arango ORCID,Stephen R. Marder ORCID,Dragana Bugarski‐Kirola

Live enrichment

PubMed:40181715 PMC:PMC12809779 OpenAlex:https://openalex.org/W4409170999

Acadia Pharmaceuticals Inc

FWCI

3.47

Citation Percentile

0.9%

Influential Citations

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://academic.oup.com/schizophreniabulletin/advance-article-pdf/doi/10.1093/schbul/sbaf034/62858591/sbaf034.pdf

publisherhttps://academic.oup.com/schizophreniabulletin/advance-article-pdf/doi/10.1093/schbul/sbaf034/62858591/sbaf034.pdf

publisherhttps://academic.oup.com/schizophreniabulletin/article-pdf/52/1/sbaf034/62858591/sbaf034.pdf

journalhttps://doi.org/10.1093/schbul/sbaf034

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40181715

Fields of Study

Schizophrenia research and treatmentTryptophan and brain disordersNeurotransmitter Receptor Influence on BehaviorMedicineHumansAdultSchizophreniaDouble-Blind MethodPiperidinesMaleFemaleMiddle AgedUreaYoung AdultAntipsychotic AgentsAdolescentDrug Therapy, CombinationOutcome Assessment, Health CareSerotonin 5-HT2 Receptor Antagonists

MeSH Terms

AdolescentAdultDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPiperidinesSchizophreniaAntipsychotic AgentsUreaOutcome Assessment, Health CareYoung AdultSerotonin 5-HT2 Receptor Antagonists

Keywords

PlaceboRandomized controlled trialAdverse effectMedicineInternal medicinePlacebo-controlled studyClinical Global ImpressionAntipsychoticSchizophrenia (object-oriented programming)Positive and Negative Syndrome ScalePsychosisPsychologyDouble blindPsychiatryPathologyAtypical Antipsychotic5-ht2aAnhedoniaAvolitionNsa-16Serotonin 5-Ht2 Receptor Antagonists

Sustainable Development Goals

SDG 0: Good health and well-being